

Artificial Intelligence/Machine Learning in Pharma Analysis and Quality Control: A Real-World Upgrade

Kishor Jain^{1,*}, Deepali Kadam², Sarathi Thakur³, Pranali Dhole³

¹Department of Pharmaceutical Chemistry, R.J.S.P.M.'s College of Pharmacy, Dudulgaon, Pune, Maharashtra, INDIA.

²Department of Pharmaceutical Chemistry, Sandip Institute of Pharmaceutical Sciences, Nashik, Maharashtra, INDIA.

³Department of Pharmaceutical Quality Assurance, RJSPM's College of Pharmacy, Dudulgaon, Pune, Maharashtra, INDIA.

ABSTRACT

Pharmaceutical analysis and quality control are now being transformed by Artificial Intelligence (AI) and Machine Learning (ML) through remarkable improvement in speed, accuracy, reliability, robustness of analysis methods. This review is to explore the integration of these tools into raw material inspection, in-process monitoring, and finished product analysis. A comprehensive survey of published literature, regulatory documents, and case studies was conducted. Key AI/ML paradigms Supervised, Unsupervised, Deep learning, Reinforcement learning, NLP; as the most important AI/ML paradigms were analysed, besides chemometrics and data management strategies in context to pharmaceuticals. Applications of AI/ML have demonstrated significant improvements in predictive quality assurance, defect detection, impurity profiling, and stability prediction. Further, their integration with Process Analytical Technology (PAT) and digital twins have enabled real-time monitoring and proactive quality management. The adoption of AI/ML is a paradigm shift from reactive to proactive Quality Control. Though data quality, regulatory compliance, and ethical considerations pose challenges, the future trends namely, integration of the explainable AI, federated learning, and robotics do promise robust, transparent, and efficient pharmaceutical quality systems.

Keywords: Artificial intelligence (AI), Machine learning (ML), Pharmaceutical Analysis and Quality Control, Process Analytical Technology (PAT).

Correspondence:

Dr. Kishor Jain

Department of Pharmaceutical Chemistry, R.J.S.P.M.'s College of Pharmacy, Dudulgaon-412105, Pune, Maharashtra, INDIA.

Email: drkishorsjain@gmail.com

Received: 21-10-2025;

Revised: 28-11-2025;

Accepted: 24-12-2025.

INTRODUCTION

The Pharma industry makes safe drugs that actually work.¹ Quality control ensures that happens. Artificial Intelligence and machine learning are changing the game making it faster and more accurate.^{2,3}

A Brief on Pharmaceutical Analysis and Quality Control

QC encompasses analysis of raw materials, in process analysis during production, and analysis of finished products before their dispatch. Every batch has to comply with standards for identity, strength, purity, stability. Without robust QC, the guarantee for the safety or efficacy of the products can't be given. It is actually compulsory under the Good Manufacturing Practices (GMP).

Traditional QC methods are often painful as they take substantial time, constant attention and manual work, often leading to mistakes.^{4,5} This leads to bad data and product recalls. Modern instruments produce size-able data on the analyses carried out by chromatographic, spectroscopic and, mass spectrometric means. Managing this huge data is rather difficult. Presently there is more reliance on HPLC and GC to separate and estimate compounds, Near IR and Raman spectroscopies are used for quick material checks, while mass spectrometry is employed to find impurities.^{6,7}

Artificial Intelligence and Machine Learning-An Introduction

Computers handle tasks in AI and ML, which in routine analysis are performed by humans and these involve data interpretations and elucidations, calculations, estimations and conclusions. While, AI is the broad category, its subset ML is focused on self-learning and improving algorithms.^{8,9} The main types are:

Supervised Learning: Training algorithms on labelled data for predictions, e.g., employing regression analysis to forecast products shelf life or to spot defective products.

Unsupervised Learning: Training on unlabelled data for finding different patterns. It is useful for clustering batches by impurity profiles.



DOI: 10.5530/ijper.20264489

Copyright Information :

Copyright Author (s) 2026 Distributed under Creative Commons CC-BY 4.0

Publishing Partner : Manuscript Technomedia. [www.mstechnomedia.com]

Deep Learning: This is quite an improved and developed ML that uses multi-layered neural networks. AI is not new, it was present since the 1950s, but now it is relevant due to the large amount of data, the existence of high-performance computers, and improved algorithms. Pharma produces “Data Mountains”, on research, development, manufacturing and here, AI has its way.¹⁰ These tools are much more effective in processing complex data than the old methods which recognise patterns that we would miss.¹¹

Rationale for AI/ML Adoption in Pharma QA/QC

Speed, accuracy and efficiency are basically necessities in the pharmaceutical industry by AI.¹² The processes of new drug discovery and development take more than 10-15 years and are associated with billions of dollars. This predictive quality management turns quality management into proactive because mundane jobs get automated.¹³ Rather than detect problems once a batch has been made, the ML models help predict the problems in real time such that you can fix them instantly.¹⁴ Measures are also more precise and consistent and less variable in AI. It is not only an upgrade but a brand-new thinking that will make the manufacturing safer, cheaper and more responsive.

METHODOLOGY/SEARCH STRATEGY

A narrative approach has been employed in preparing this review to outline present applications of AI/ML in pharmaceutical analysis and quality control. Literature searches were made through PubMed, Scopus, and Google Scholar using keywords; Artificial Intelligence, Machine Learning, Pharmaceutical Quality Control, Process Analytical Technology, Chemometrics. Besides this the regulatory documents from FDA, EMA, and ICH were also consulted. Inclusion criteria: peer-reviewed articles, regulatory guidelines, and case studies published from 2000-2025. Exclusion criteria: non-peer-reviewed sources and studies unrelated to pharmaceutical applications.

FOUNDATIONAL CONCEPTS OF AI AND ML FOR PHARMACEUTICAL APPLICATIONS

Using AI rightly in pharma means understanding core concepts and the industry's weird data challenges, key methods and why data management matters, plus how chemometrics fits.

Key AI/ML Algorithms and Techniques

Different problems need different algorithms.¹⁵

Supervised Learning

Train algorithms on data with inputs and correct outputs. Goal is learning how to predict new things.

Regression: Predicts numbers, forecasting drug stability or shelf life based on temperature, humidity, formulation.^{16,17} Also predicts solubility and other properties needed for formulation.¹⁸

Classification: Predicts categories, used heavily for defect detection models to classify tablets or vials as pass or fail based on visual data.¹⁹ Also checks critical quality attributes in method development.

Unsupervised Learning

Train algorithms on unlabelled data to discover patterns.

Clustering: Groups similar items, in QC, finds patterns in impurity profiles across batches, helps spotting process variations or contamination. Can also group suppliers by quality trends.

Detection of Anomalies: Detecting rare events that are unexpected. This is very critical for identifying manufacturing problems in real-time and include, sudden temperature or pressure changes, signalling equipment issues.²⁰

Deep Learning

Learning complex patterns with multi-layer deep neural networks. Processes big data volumes of unstructured data such as images and time-series.

CNNs (Convolutional Neural Networks): It works well with pictures. Powers AI to automatically scan tablets, capsules, vials, etc. identify flaws such as cracks, particles, packaging mistakes quickly and with accuracy.

RNNs (Recurrent Neural Networks): Processes sequential data, which is suitable in the real-time monitoring of processes. Calculates sensor values to infer the future or identify anomaly based on the past patterns.

Reinforcement Learning (RL)

Trains an agent to act in order to maximize rewards.²¹ A RL agent may also learn to turn the temperature or stirring speed on and off to maintain things at an optimum.

Natural Language Processing (NLP)

Let's computers understand human language. In pharma, NLP digs through scientific literature, regulatory documents, adverse event reports. Automates extracting critical info like drug interactions or trial outcomes, keeps compliance up with changing regulations.²² The main AI/ML paradigms, viz.; Supervised Learning, Unsupervised Learning, Deep Learning, Reinforcement Learning, and NLP, are widely applied in pharmaceutical contexts (Figure 1).

Data Management and Pre-processing in Pharmaceutical Context

AI models only work with good training data.²³ In pharma, that's hard. Data comes from everywhere, analytical instruments, manufacturing sensors, clinical databases.²⁴ These silos create messy formats, missing values, zero standardization. and kill the model's performance.²⁵

Therefore, data management and pre-processing are critical:

Data Cleaning: Mend broken things, fix bugs and duplicated data.²⁶

Data Integration: This is the process of combining data of various sources into a unified entity.²⁷

Data Normalization/Scaling: Normalize all features to similar scales, thus, some of them are not predominant.²⁸

Feature Engineering: This involves transformation of raw data into formats which the ML models identify better, to create new variables or combine existing ones.

Chemometrics and its Integration with AI/ML

Chemometrics uses math and stats to pull information from chemical data. Been a cornerstone of analytical processing in pharma forever, especially for spectral analysis. Traditional statistical techniques like PCA for dimensionality reduction and PLS for calibration have been standard for years.²⁹

AI/ML pushes these methods further. Chemometrics methods work with linear relationships, AI/ML grabs complex, non-linear patterns. Deep learning models analyze spectral data from NIR, Raman, FTIR spectroscopy way better than old methods; for faster, more accurate raw material verification, process control, counterfeit detection.³⁰ By mixing chemometrics principles with AI's predictive power, analysts get way more complete understanding of their data with stronger quality control.

APPLICATIONS OF AI AND ML IN PHARMACEUTICAL ANALYSIS

AI and ML touch every stage of pharma analysis, initial material checks to final product testing. Not just automating what exists, enabling new, more efficient methods.

Raw Material Inspection and Verification

The first step in the manufacturing process of drugs is the checking of incoming raw materials. This was altered by AI/ML with fast methods such as NIR or Raman spectroscopy. Machine learning models in particular, classification algorithms are trained on spectral fingerprints of approved materials. Quickly identifying and inspecting in-coming material in only a few seconds, accelerates manufacturing release.³¹ The same case works wonders with counterfeits and these counterfeit products will not be similar to genuine spectral signatures, which will be instantly detected and discredited.³²

In-Process Control (IPC) and Real-time Monitoring

PAT is a monitoring technology that is designed and operated to control production based on measurements of key material at real-time. Combining AI/ML and PAT can have intelligent self-optimizing systems. ML models monitor Critical Process

Parameters and Critical Quality Attributes at the process endpoint (i.e. powder blend uniformity) with spectroscopic sensor data.³³ Models predict deviations prior to resulting in out-of-spec products so that they can be fixed on the fly.³⁴ AI-based real-time anomaly detectors will indicate unusual sensor readings, trends indicating equipment malfunction or human errors. Thereafter, prompt fixes shall eliminate batch failure.^{35,36} AI/ML integration with PAT enables continuous monitoring and predictive quality assurance across the manufacturing workflow (Figure 2).

Finished Product Analysis

Final product analysis gets huge benefits from AI/ML, leading to better accuracy and faster results.

Visual Inspection and Defect Detection

Manual visual inspections are tedious and subjective. AI-powered computer vision using CNNs have automated this with better speed and consistency. Systems inspect thousands of tablets, capsules, vials, packaging per minute, catching subtle physical defects, foreign particles, label errors humans might miss.³⁷ This cuts inspection time and labor costs while improving reliability.³⁸

Impurity Profiling and Quantification

Accurately finding and measuring impurities is essential for drug safety.³⁹ ML algorithms increasingly dig through complex chromatographic and spectroscopic data from HPLC or GC-MS.^{40,41} Models identify and quantify trace impurities with high sensitivity and accuracy, even in messy samples. Predictive models also forecast impurity formation under different stress conditions, insights for process optimization.⁴²

Stability Studies and Shelf-Life Prediction

Traditional stability studies are long and expensive, need years of real-time data. AI/ML offers solution through predictive

Supervised Learning		Unsupervised Learning	
Regression Shelf-life Prediction Solubility Forecasting	Classification Defect Detection Pass/Fail Analysis	Clustering Impurity Profiling Batch Grouping	Anomaly Detection Process Deviation Identification
Deep Learning		Emerging Applications	
CNNs Visual Inspection of Tablets/Vials	RNNs Real-Time Process Monitoring	Reinforcement Learning Process Optimization	NLP Regulatory Document Analysis

Figure 1: An overview of the AI & ML paradigms and their specific applications in pharmaceutical analysis and quality control. Each type of the algorithm is matched with representative application cases, demonstrating the versatility, scope and potential of AI & ML across the drug lifecycle, viz.; from raw material inspection to finished product certification.




Figure 2: Integrated AI/ML workflow in pharmaceutical manufacturing and quality control. An illustration of the key intervention points wherein, AI/ML technologies enhance traditional processes, from raw material verification to final batch release. The arrows are indicative of continuous data flow and feedback loops that enable real-time quality optimization and predictive quality assurance.

modelling which forecasts drug stability under various conditions based on limited accelerated stability data. Analyzing historical datasets, models accurately predict degradation kinetics, more efficient accelerated stability testing, and faster shelf life determination.

Analytical Method Development and Validation

Developing robust validated analytical methods is a bottleneck. AI/ML driven platforms optimize this by smartly exploring experimental conditions. ML algorithms predict optimal chromatographic conditions like column type, mobile phase composition, and flow rate for given separations, cuts way down on costly experimental runs. AI ML tools also help with automated method validation, ensuring accuracy, precision, robustness by analyzing performance data and flagging problems.

Drug Formulation and Excipient Selection

Picking excipients and designing stable, bioavailable formulations are complex problems. ML models train on databases of material properties and formulation outcomes to predict optimal excipient combinations and designs.⁴³ Data-driven approach speeds up new drug development by identifying promising candidates with

better properties like solubility and bioavailability early in the process.⁴⁴

Pharmacopoeial Compliance and Regulatory Document Analysis

Staying compliant with global pharmacopoeias (USP, Ph. Eur.) and regulatory guidelines is labour intensive and error prone. NLP's powerful here. The NLP models can automatically scan, analyze, and extract critical information from pharmacopoeias and regulatory documents and can create real-time alerts on updates affecting manufacturing or analytical methods. This ensures compliance, and helps in proactive auditing and continuous improvement.

APPLICATIONS OF AI AND ML IN PHARMACEUTICAL QUALITY CONTROL (BEYOND ANALYTICAL)

AI and ML's reach goes way past the lab and covers quality management across entire pharma value chain.⁴⁵ These apps shift the industry from reactive, inspection-based to proactive, predictive, tackling problems before they mess up quality or patient safety.⁴⁶




Figure 3: Paradigm shift from reactive to proactive quality control through AI/ML implementation: Traditional QC (top) identifies problems only after batch completion, leading to costly rework or rejection. AI-enabled predictive quality assurance (bottom) uses real-time data and machine learning models to forecast potential quality issues, enabling Immediate corrective actions and ensuring continuous process optimization.

Predictive Quality Assurance (PQA)

Predictive Quality Assurance uses historical and real-time data to forecast potential quality problems.⁴⁷ Analyzing datasets from manufacturing sensor readings, environmental data, batch records to ML models spot early signs of high-risk batches.^{48,49} Proactive approach lets manufacturers step in and adjust processes before deviations happen, cuts down on rework, reduces waste, improves efficiency. Predictive analytics moves quality control from point-in-time checks to continuous, data-driven systems.⁵⁰ Predictive Quality Assurance represents a paradigm shift from reactive to proactive QC, as illustrated in (Figure 3).

Root Cause Analysis and CAPA (Corrective and Preventive Actions)

Traditional Root Cause Analysis and CAPA implementation drag on forever. AI, especially through NLP and machine learning, changes this. AI-driven systems chew through large volumes of messy data from deviation reports, complaints, audit findings, quickly finding hidden patterns that humans miss. Improves root cause identifies accuracy and lets system suggest effective fixes based on similar past cases, streamlines CAPA, stops recurring problems.

Equipment Maintenance and Calibration

In pharma manufacturing, surprise equipment failure causes major production delays and money loss.⁵¹ AI and ML shift from scheduled or reactive maintenance to predictive maintenance. Analyzing real-time sensor data like vibration, temperature,

pressure the ML algorithms accurately forecast equipment failures before they happen.^{52,53} Maintenance gets done when actually needed, cuts downtime, optimizes resources. AI also watches performance trends to ensure continuous calibration, validates machinery, operates within defined parameters, keeps product quality consistent.

Supply Chain Quality and Traceability

Global pharma supply Chains are complex, vulnerable to counterfeiting, diversion, quality problems.⁵⁴ AI adds intelligence to tackle these risks. ML models continuously watch raw material and intermediate quality moving through supply chain, flag suspicious patterns indicating compromised integrity.^{55,56} Mix AI with blockchain for robust traceability. Blockchain creates secure, unchangeable ledger of every transaction, AI analyzes data in real-time to catch anomalies and verify authenticity, makes it super hard for fake products to get into legitimate supply chain.^{57,58}

Batch Release and Certification

Final batch release is a critical regulatory step based on reviewing extensive analytical, process and quality data. AI-assisted systems streamline this by integrating and analyzing all relevant data like raw material certificates to in-process control data and final analysis results. AI quickly spots out-of-spec or out-of-trend data, provides comprehensive, risk-based assessment supporting batch release decisions. AI also automates generating Certificates of Analysis and other compliance docs, cuts admin burden and

human error. AI-driven approach speeds up batch release while ensuring better data integrity and compliance.

CHALLENGES AND CONSIDERATIONS FOR AI/ML ADOPTION IN PHARMA QA/QC

AI/ML's potential in pharma QA/QC is massive, but getting widespread adoption faces big challenges.⁵⁹ Hurdles span technical, regulatory, ethical, organizational matters and need strategic planning to overcome.

Data Challenges

Any successful AI/ML models building on data, in pharma, is tricky.⁶⁰ Important issues are quality, completeness, consistency.⁶¹ Historically, data has been collected for specific reasons and might be incomplete, have errors, lack standardized formats which may be unsuitable for training solid models. Compounded by data silos have critical info from different departments like R&D, manufacturing, QC stored in incompatible, fragmented systems, blocks creating comprehensive datasets.⁶² While deep learning loves large datasets, industry often deals with small datasets for rare events or new compounds, hard to train models confidently. Finally, handling sensitive stuff like patient data from clinical trials brings major challenges with data privacy and security, requires strict adherence to regs like GDPR and HIPAA.^{63,64}

Regulatory Compliance and Validation

Pharma's super regulated nature is major barrier to AI adoption.⁶⁵ Regulatory bodies like FDA and EMA have tough requirements for any system impacting product quality or patient safety.^{66,67} Validating AI/ML algorithms is especially complex as traditional validation methods don't fit adaptive or "learning" systems.⁶⁸ Core problem's the "black box" nature of many complex AI models are difficult or impossible to understand how model reached a decision.⁶⁹ This lack of transparency is unacceptable for regulators, creates pressing need for Explainable AI (XAI), aims to make model decisions interpretable and justifiable.⁷⁰ Industry's also stuck with lack of specific, formal regulatory guidelines for validating and governing AI/ML systems, though draft guidance starting to show up.^{71,72}

Ethical Considerations

Using AI in a field directly hitting human health raises critical ethical stuff.⁷³ Primary concern's bias in algorithms, can pop up if training data's unrepresentative or biased like historical data reflecting past biases in clinical trials or manufacturing.⁷⁴ Could lead to models performing badly for certain populations or product types, worsens existing health disparities. Issue of accountability for AI-driven decisions is also big.⁷⁵ In manufacturing deviation or product recall, unclear who's legally and ethically responsible when AI model makes decision, clear frameworks for human oversight and responsibility are essential.⁷⁶

Integration with Existing Systems

Many pharma companies run established legacy systems for manufacturing execution, lab info management, enterprise resource planning.⁷⁷ Compatibility of new AI/ML tools with legacy infrastructure is major technical hurdle. Data transfer between old and new systems can be slow and error-prone, creates data integrity risks.⁷⁸ Successfully integrating AI needs significant investment in robust IT infrastructure and cybersecurity to ensure data flow's seamless and secure against increasing cyber threats hitting the industry.^{79,80}

Talent and Expertise

Successful AI implementation depends on skilled people.⁸¹ Major challenge is shortage of data scientists and AI/ML experts with deep pharma domain knowledge.⁸² Professionals understanding both drug manufacturing intricacies and technical aspects of AI algorithms are rare. Talent gap means focus on upskilling existing workforce like training QA professionals, chemists, and engineers in data literacy and AI fundamentals so they can effectively work with and leverage new intelligent systems.⁸³

Cost of Implementation

While AI promises long-term savings, initial cost of implementation can be heavy. Includes significant investment in techniques like high-performance computing and cloud infrastructure, specialized software, attracting or training qualified people. Companies got to perform careful return on investment justification, show how AI will lead to real benefits like reduced batch rejection rates, faster time-to-market, improved operational efficiency to get internal buy-in and justify the investment.^{84,85}

FUTURE TRENDS AND OUTLOOK

As AI and ML keep maturing, their future in pharma analysis and quality control promises even more transformation.⁸⁶ Focus is shifting from just automating tasks to creating fully integrated, intelligent ecosystems. Evolution is driven by advances in specialized AI domains and collaborative efforts across industry to tackle challenges in highly regulated environment.⁸⁷

Explainable AI (XAI) in Pharma

While "black box" nature of many AI models is current challenge, Future is centered on Explainable AI.⁸⁸ XAI is crucial for developing transparent models that justify predictions in human-understandable ways. This transparency is non-negotiable for regulatory acceptance from FDA and EMA and lets inspectors understand logic behind AI decisions, like pass/fail calls on product batches.^{89,90} Research in XAI focuses on developing new algorithms providing explanations and confidence scores alongside outputs, building necessary trust for high-stakes QA/QC apps.⁹¹

Federated Learning and Collaborative AI

Data silos within and between organizations are major barrier.⁹² Federated learning offers solution by enabling sharing insights without sharing raw data.⁹³ In this the, AI model trains locally on company's data, only learned parameters (not data itself) get shared and aggregated with other companies to create more robust global model. Approach helps collaborative AI and benchmarking across different manufacturing sites or even competing companies, lets them leverage collective knowledge to improve process efficiency and quality standards while keeping strict data privacy and intellectual property.^{94,95}

Digital Twins and Simulation

Concept of digital twin includes virtual replica of physical process, product, or system set to revolutionize pharma manufacturing.^{96,97} AI-powered digital twins of manufacturing lines can run simulations under various conditions to optimize process parameters, predict impact of changes, identifies potential bottlenecks without physical experimentation. Provides powerful environment for real-time optimization and predictive modeling, lets manufacturers fine-tune processes for max yield and quality.⁹⁸ For example a, digital twin can simulate how tablet compression would behave under slight humidity changes, inform process control systems in real-time.

Integration with Robotics and Automation

Future of pharma manufacturing and QC will see complete integration of AI with robotics and automation.⁹⁹ AI serves as "brain" directing robotic systems to perform complex tasks with precision and speed which includes automated sample preparation and analysis in fully robotic QC labs to intelligent sorting and packaging on manufacturing lines.^{100,101} This synergy leads to fully automated QC labs and manufacturing lines, cuts human intervention to minimum, eliminates human error, enables 24/7 operation with crazy consistency and efficiency.

AI in Personalized Medicine and Small Batch Production

Shift towards personalized medicine requires fundamental rethinking of QC.¹⁰² Instead of large-scale, one-size-fits-all manufacturing, industry's moving toward producing individualized therapies in small batches. AI's essential for adapting QC processes for individualized therapies and small-batch production. AI models quickly analyze unique attributes of each small batch, ensuring final product hits required quality standards.¹⁰³ Capability lets manufacturers maintain tough quality control even with high-variability products, makes personalized medicine scalable.^{104,105}

Regulatory Evolution and Industry Collaboration

For AI to hit full potential, forward-looking regulatory framework is essential.¹⁰⁶ Regulatory bodies like FDA are already issuing

draft guidance on AI use in drug development, shows willingness to adapt.¹⁰⁷ Future will bring more definitive guidelines balancing innovation with patient safety. To shape these guidelines effectively, critical need is for close industry-academia-regulatory body collaboration.¹⁰⁸ Working together, stakeholders can establish best practices, develop standardized validation protocols, create shared understanding of AI's capabilities and limits, and pave way for faster, safer, more innovative pharma landscape.^{109,110}

DISCUSSION

The integration of AI/ML into pharmaceutical quality control and analysis, involves technological advancement and regulatory challenges. Efficiency gains are definitely observed through their applications in raw material analysis, in-process monitoring, and finished product analysis. Barriers involve data inaccessibility, lack of standardized validation protocols, and ethical biases. As compared to the traditional QC, the AI/ML supported QC offers better predictive capabilities to reduce batch failures and enhance patient safety. The reviewed literature highlights the need for Explainable AI to ensure regulatory acceptance. Collaborative models like federated learning could overcome data privacy concerns, while digital twins and robotics promise fully automated QC environments, in near future.

CONCLUSION

Bringing AI and ML into pharma analysis and quality control marks major shift from traditional, reactive methods to proactive, data-driven approaches.¹¹¹ This overview explores how AI/ML are transforming nearly every part of drug lifecycle- initial raw material inspection to final product certification.

Benefits are big and far-reaching. Extensive literature shows AI-powered systems deliver real improvements in efficiency by automating time-consuming tasks like visual inspection and method development.¹¹² They boost accuracy and consistency, enable more reliable defect detection and impurity profiling than manual processes.¹¹³ These improvements lead to major cost cuts by minimizing waste, reducing rework, optimizing equipment maintenance through predictive analytics.¹¹⁴ Ultimately, most critical benefit is boosting patient safety, as AI systems help ensure solid quality and integrity of drug products hitting the market.¹¹⁵

However, journey to fully intelligent QA/QC ecosystem isn't smooth. Key hurdles include beating data-related problems like quality, integrity, pervasive issue of data silos.¹¹⁶ Industry must also navigate complex landscape of regulatory compliance, particularly tackling "black box" problem of AI models through development of Explainable AI to build trust and ensure transparency.¹¹⁷ Plus, ethical stuff regarding algorithmic bias, need for specialized talent, and significant cost of implementation remain critical talking points.¹¹⁸

Looking ahead, AI/ML's transformative potential is poised to shape future of pharma manufacturing and quality assurance.¹¹⁹ Industry is already moving towards more sophisticated apps like federated learning for collaborative insights, use of digital twins for real-time process optimization, full integration of AI with robotics for autonomous labs.¹²⁰ Future also holds promise of adapting these techniques to unique demands of personalized medicine and small-batch production.¹²¹ As regulatory bodies and industry keep collaborating on establishing clear governance framework, full-scale AI adoption will not only be possible but will become an essential competitive advantage, driving continuous improvement and ensuring highest quality standards for next generation of medicines.^{122,123}

ACKNOWLEDGEMENT

The authors gratefully acknowledge the support of their respective institutions and colleagues who contributed insights during manuscript preparation. Special thanks to the editorial team and peer reviewers for their constructive feedback.

ABBREVIATIONS

AI and ML: Artificial Intelligence and Machine Learning; **QA:** Quality Assurance; **QC:** Quality Control; **PAT:** Process Analytical Technology; **HPLC:** High Performance Liquid Chromatography; **FDA:** Food and Drug Administration (USA); **EMA:** European Medicines Agency; **GDPR:** General Data Protection Regulation; **HIPAA:** Health Insurance Portability and Accountability Act; **NIR:** Near-Infrared Spectroscopy; **FTIR:** Fourier Transform Infrared Spectroscopy; **GC:** Gas Chromatography; **GC-MS:** Gas Chromatography-Mass Spectrometry; **GMP:** Good Manufacturing Practices; **R&D:** Research and Development; **XAI:** Explainable Artificial Intelligence; **CNNs:** Convolutional Neural Networks; **RNNs:** Recurrent Neural Networks; **RL:** Reinforcement Learning; **NLP:** Natural Language Processing; **PCA:** Principal Component Analysis; **PLS:** Partial Least Squares; **IPC:** In-Process Control; **CAPA:** Corrective and Preventive Actions; **USP:** United States Pharmacopeia; **Ph. Eur.:** European Pharmacopoeia; **PQA:** Predictive Quality Assurance.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

AUTHOR CONTRIBUTIONS

Kishor Jain: Conceptualization, manuscript drafting, critical revision, and overall supervision.

Deepali Kadam: Review of QC applications, data interpretation, and drafting of foundational concepts.

Sarathi Thakur: Literature review, figure preparation, and manuscript editing.

Pranali Dhole: Compilation of references, formatting, and proofreading.

REFERENCES

- DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. *J Health Econ.* 2016;47:20-33.
- Ekins S. The next era: deep learning in pharmaceutical research. *Pharm Res.* 2016;33(11):2594-2603.
- Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. *Drug Discov Today.* 2018;23(6):1241-50.
- Chatterjee S. FDA perspective on continuous manufacturing. *IFPAC Annual Meeting.* 2012.
- Shah N. Pharmaceutical supply chains: key issues and strategies for optimisation. *Comput Chem Eng.* 2004;28(6-7):929-41.
- Snyder LR, Kirkland JJ, Dolan JW. *Introduction to Modern Liquid Chromatography.* 3rd ed. Hoboken (NJ): John Wiley & Sons; 2010.
- Grob RL, Barry EF. *Modern Practice of Gas Chromatography.* 4th ed. Hoboken (NJ): John Wiley & Sons; 2004.
- Mitchell TM. *Machine Learning.* New York (NY): McGraw-Hill; 1997.
- Bishop CM. *Pattern Recognition and Machine Learning.* New York (NY): Springer; 2006.
- Mamoshina P, Vieira A, Putin E, Zhavoronkov A. Applications of deep learning in biomedicine. *Mol Pharm.* 2016;13(5):1445-54.
- Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. *Nat Rev Drug Discov.* 2019;18(6):463-77.
- Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nat Rev Drug Discov.* 2010;9(3):203-14.
- Nasr MM, Krumme M, Matsuda Y, et al. Regulatory perspectives on continuous pharmaceutical manufacturing: moving from theory to practice. *J Pharm Sci.* 2017;106(11):3199-206.
- Su Q, Ganesh S, Moreno M, et al. A perspective on Quality-by-Control (QbC) in pharmaceutical continuous manufacturing. *Comput Chem Eng.* 2019;125:216-31.
- Kourti T. Process analytical technology beyond real-time analyzers: the role of multivariate analysis. *Crit Rev Anal Chem.* 2006;36(3-4):257-78.
- Waterman KC, Adami RC. Accelerated aging: prediction of chemical stability of pharmaceuticals. *Int J Pharm.* 2005;293(1-2):101-25.
- Yoshioka S, Stella VJ. *Stability of Drugs and Dosage Forms.* Boston (MA): Kluwer Academic Publishers; 2000.
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev.* 2001;46(1-3):3-26.
- Schmidt A, Molnár I, Refinery P. Completely automated LC method development on QbD basis using modeling software and LC-MS. *LCGC N Am.* 2013;31(11):875-84.
- Chandola V, Banerjee A, Kumar V. Anomaly detection: a survey. *ACM Comput Surv.* 2009;41(3):1-58.
- Sutton RS, Barto AG. *Reinforcement Learning: An Introduction.* 2nd ed. Cambridge (MA): MIT Press; 2018.
- Lee J, Yoon W, Kim S, et al. BioBERT: a pre-trained biomedical language representation model for biomedical text mining. *Bioinformatics.* 2020;36(4):1234-40.
- Keogh E, Mueen A. *Curse of dimensionality.* In: Sammut C, Webb GI, editors. *Encyclopedia of Machine Learning and Data Mining.* Boston (MA): Springer; 2017.
- Batista GEAPA, Monard MC. An analysis of four missing data treatment methods for supervised learning. *Appl Artif Intell.* 2003;17(5-6):519-33.
- García S, Luengo J, Herrera F. *Data Preprocessing in Data Mining.* Cham (Switzerland): Springer; 2015.
- Rahm E, Do HH. Data cleaning: problems and current approaches. *IEEE Data Eng Bull.* 2000;23(4):3-13.
- Lenzerini M. Data integration: a theoretical perspective. *Proc ACM SIGMOD-SIGACT-SIGART Symposium Principles of Database Systems.* 2002: 233-46.
- Han J, Pei J, Kamber M. *Data Mining: Concepts and Techniques.* 3rd ed. Amsterdam (Netherlands): Elsevier; 2011.
- Brereton RG, Lloyd GR. Partial least squares discriminant analysis: taking the magic away. *J Chemom.* 2014;28(4):213-25.
- Roggo Y, Chalou P, Maurer L, et al. A review of near infrared spectroscopy and chemometrics in pharmaceutical technologies. *J Pharm Biomed Anal.* 2007;44(3):683-700.
- De Beer T, Burggraef A, Fonteyne M, et al. Near infrared and Raman spectroscopy for in-process monitoring of pharmaceutical production processes. *Int J Pharm.* 2011;417(1-2):32-47.
- Dégardin K, Roggo Y, Been F, Margot P. Understanding and fighting the medicine counterfeit market. *J Pharm Biomed Anal.* 2014;87:167-75.
- Fonteyne M, Gildemyn D, Peeters E, et al. Moisture and drug solid-state monitoring during a continuous drying process. *Eur J Pharm Biopharm.* 2014;87(3):616-28.

34. Singh R, Sahay A, Karry KM, et al. Implementation of an advanced model predictive control system for continuous tablet manufacturing. *Int J Pharm.* 2014;473(1-2):38-44.
35. García-Muñoz S, Dolph S, Ward HW. Handling uncertainty in establishing design space for pharmaceutical manufacture. *Comput Chem Eng.* 2010;34(7):1098-107.
36. Tomba E, Facco P, Bezze F, Barolo M. Latent variable modeling for Quality-by-Design. *Int J Pharm.* 2013;457(1):283-97.
37. Du CJ, Sun DW. Image processing as an emerging tool for food quality evaluation. *Trends Food Sci Technol.* 2004;15(5):230-49.
38. Alcalà M, Blanco M, Bautista M, González JM. On-line monitoring of granulation by NIR spectroscopy. *J Pharm Sci.* 2010;99(1):336-45.
39. ICH. ICH Q3A(R2): Impurities in New Drug Substances. 2006.
40. Teasdale A, Elder D, Nims RW, et al. ICH M7: assessment and control of mutagenic impurities. *Regul Toxicol Pharmacol.* 2013;67(3):353-68.
41. Elder DP, Facchine KL, Levy S, et al. Understanding extractables and leachables: an overview. *Am Pharm Rev.* 2007;10(6):46-53.
42. Reynolds DW, Facchine KL, Mullaney JF, et al. Forced degradation studies: current perspectives. *Pharm Technol.* 2002;26(2):48-56.
43. Liu LX, Marziano I, Bentham AC, et al. Effect of particle properties on flowability of ibuprofen powders. *Int J Pharm.* 2008;362(1-2):109-17.
44. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for the biopharmaceutics classification system. *Pharm Res.* 1995;12(3):413-20.
45. Nasr MM, Krumme M, Matsuda Y, et al. Regulatory perspectives on continuous pharmaceutical manufacturing. *J Pharm Sci.* 2017;106(11):3199-206.
46. Lee SL, O'Connor TF, Yang X, et al. Modernizing pharmaceutical manufacturing: from batch to continuous production. *J Pharm Innov.* 2015;10(3):191-9.
47. García-Muñoz S, Luciani CV, Vaidyaraman S, Seibert KD. Mechanistic models for design space development in QbD. *Org Process Res Dev.* 2015;19(8):1012-23.
48. Peterson JJ. Bayesian statistical approaches for design space identification. *J Biopharm Stat.* 2008;18(5):959-75.
49. Lebrun P, Krier F, Mantanus J, et al. Design space for spray-drying: a case study. *Eur J Pharm Biopharm.* 2012;80(1):226-34.
50. Yu LX. Pharmaceutical quality by design: an introduction. *Pharm Res.* 2008;25(4):781-91.
51. Jardine AKS, Lin D, Banjevic D. A review on machinery diagnostics and prognostics implementing condition-based maintenance. *Mech Syst Signal Process.* 2006;20(7):1483-510.
52. Sikorska JZ, Hodkiewicz M, Ma L. Prognostic modelling options for remaining useful life estimation in industry. *Mech Syst Signal Process.* 2011;25(5):1803-36.
53. Lei Y, Li N, Guo L, Li N, Yan T, Lin J. Machinery health prognostics: a systematic review from data acquisition to RUL prediction. *Mech Syst Signal Process.* 2018;104:799-834.
54. Mackey TK, Liang BA. The global counterfeit drug trade: patient safety and public health risks. *J Pharm Sci.* 2011;100(11):4571-9.
55. Blackstone EA, Fuhr JP Jr, Pociask S. The health and economic effects of counterfeit drugs. *Am Health Drug Benefits.* 2014;7(4):216-24.
56. Newton PN, Green MD, Fernández FM, Day NP, White NJ. Counterfeit anti-infective drugs. *Lancet Infect Dis.* 2006;6(9):602-13.
57. Casino F, Dasaklis TK, Patsakis C. A systematic literature review of blockchain-based applications. *Telemat Inform.* 2019;36:55-81.
58. Sylim P, Liu F, Marcelo A, Fontelo P. Blockchain technology for detecting falsified and substandard drugs in the supply chain. *JMIR Res Protoc.* 2018;7(9):e10163.
59. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med.* 2019;25(1):44-56.
60. Chen JH, Asch SM. Machine learning and prediction in medicine: beyond the peak of inflated expectations. *N Engl J Med.* 2017;376(26):2507-9.
61. Beam AL, Kohane IS. Big data and machine learning in health care. *JAMA.* 2018;319(13):1317-8.
62. Shah NH, Milstein A, Bagley SC. Making machine learning models clinically useful. *JAMA.* 2019;322(14):1351-2.
63. Regulation (EU) 2016/679. General Data Protection Regulation (GDPR). *Off J Eur Union.* 2016; L119:1-88.
64. HIPAA. Health Insurance Portability and Accountability Act of 1996. *Pub. L.* 104-191; 110 Stat. 1936.
65. Ekins S, Puhl AC, Zorn KM, et al. Exploiting machine learning for end-to-end drug discovery and development. *Nat Mater.* 2019;18(5):435-41.
66. Food and Drug Administration. Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. 2021. Available from: <https://www.fda.gov/ps/ps/www.fda.gov/>
67. European Medicines Agency. Reflection paper on the use of Artificial Intelligence (AI) in the lifecycle of medicines. 2022. Available from: <https://www.ema.europa.eu/>
68. Food and Drug Administration. Software as a Medical Device (SaMD): Clinical Evaluation. 2017. Available from: <https://www.fda.gov/>
69. Rudin C. Stop explaining black box machine learning models and use interpretable models instead. *Nat Mach Intell.* 2019;1(5):206-15.
70. Lundberg SM, Lee SI. A unified approach to interpreting model predictions. *Adv Neural Inf Process Syst.* 2017;30:4765-74.
71. Food and Drug Administration. Proposed Regulatory Framework for Modifications to AI/ML-Based SaMD. 2019. Available from: <https://www.fda.gov/>
72. European Medicines Agency. Draft reflection paper on the use of Artificial Intelligence (AI) in the lifecycle of medicines. 2021.
73. Floridi L, Cowls J, Beltramini M, et al. AI4People—an ethical framework for a good AI society. *Minds Mach.* 2018;28(4):689-707.
74. Rajkomar A, Hardt M, Howell MD, Corrado G, Chin MH. Ensuring fairness in machine learning to advance health equity. *Ann Intern Med.* 2018;169(12):866-72.
75. Mittelstadt B. Principles alone cannot guarantee ethical AI. *Nat Mach Intell.* 2019;1(11):501-7.
76. Jobin A, Ienca M, Vayena E. The global landscape of AI ethics guidelines. *Nat Mach Intell.* 2019;1(9):389-99.
77. Ross J, Stevenson F, Lau R, Murray E. Factors that influence the implementation of e-health: a systematic review. *Implement Sci.* 2016;11(1):146.
78. Kruse CS, Karem P, Shifflett K, et al. Evaluating barriers to adopting telemedicine worldwide. *J Telemed Telecare.* 2018;24(1):4-12.
79. Gordon WJ, Catalini C. Blockchain technology for healthcare. *Comput Struct Biotechnol J.* 2018;16:224-30.
80. Kruse CS, Frederick B, Jacobson T, Monticone DK. Cybersecurity in healthcare: a systematic review. *Technol Health Care.* 2017;25(1):1-10.
81. Shortliffe EH, Sepúlveda MJ. Clinical decision support in the era of artificial intelligence. *JAMA.* 2018;320(21):2199-200.
82. Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. *Future Healthc J.* 2019;6(2):94-8.
83. Paranjape K, Schinkel M, Panday RN, Car J, Nanayakkara P. AI training in medical education. *JMIR Med Educ.* 2019;5(2):e16048.
84. Sultan AS, Elgharib MA, Tavares T, Jessri M, Basile JR. AI and deep learning in oncologic histopathology. *J Oral Pathol Med.* 2020;49(9):849-56.
85. Bohr A, Memarzadeh K. The rise of artificial intelligence in healthcare applications. In: *Artificial Intelligence in Healthcare.* Amsterdam (Netherlands): Elsevier; 2020. p. 25-60.
86. Reardon S. 'Brain organoids' grown in lab dishes. *Nature.* 2016;539(7628):269-70.
87. Heaven WD. DeepMind's protein-folding AI solves a 50-year challenge. *MIT Technol Rev.* 2020.
88. Angelov PP, Soares EA, Jiang R, Arnold NI, Atkinson PM. Explainable artificial intelligence: an analytical review. *Wiley Interdiscip Rev Data Min Knowl Discov.* 2021;11(5):e1424.
89. Arrieta AB, Díaz-Rodríguez N, Del Ser J, et al. Explainable AI: concepts, taxonomies, opportunities and challenges. *Inf Fusion.* 2020;58:82-115.
90. Gilpin LH, Bau D, Yuan BZ, Bajwa A, Specter M, Kagal L. Explaining explanations. In: *IEEE DSAA 2018.* Piscataway (NJ): IEEE; 2018. p. 80-9.
91. Molnar C. *Interpretable Machine Learning.* Munich (Germany): Lulu Press; 2020.
92. Doshi-Velez F, Kim B. Towards a rigorous science of interpretable machine learning. *arXiv.* 2017.
93. Ribeiro MT, Singh S, Guestrin C. Why should I trust you? *Proc 22nd ACM SIGKDD.* 2016: 1135-44.
94. Shrikumar A, Greenside P, Kundaje A. Learning important features through propagating activation differences. *Proc 34th ICML.* 2017;70:3145-53.
95. Smilkov D, Thorat N, Kim B, et al. *SmoothGrad.* arXiv. 2017.
96. Zeiler MD, Fergus R. Visualizing convolutional networks. In: *ECCV 2014.* Cham; 2014. p. 818-33.
97. Simonyan K, Vedaldi A, Zisserman A. Deep inside convolutional networks. *arXiv.* 2014.
98. Sundararajan M, Taly A, Yan Q. Axiomatic attribution for deep networks. *Proc 34th ICML.* 2017;70:3319-28.
99. Bach S, Binder A, Montavon G, Klauschen F, Müller KR, Samek W. Layer-wise relevance propagation. *PLoS One.* 2015;10(7):e0130140.
100. Zhang Q, Wu YN, Zhu S-C. Interpretable CNNs. In: *IEEE CVPR 2018.* Piscataway (NJ); 2018. p. 8827-36.
101. Samek W, Wiegand T, Müller KR. Explainable artificial intelligence. *ITU J.* 2017;1:1-10.
102. Holzinger A, Biemann C, Pattichis CS, Kell DB. What do we need to build explainable AI systems? *Rev Med Inform.* 2017;26(2):121-6.
103. Tjoa E, Guan C. A survey on explainable artificial intelligence (XAI). *IEEE Trans Neural Netw Learn Syst.* 2020;32(11):4793-813.
104. Belle V, Papantonis I. Principles and practice of explainable machine learning. *Front Big Data.* 2021;4:688969.
105. Katuwal GJ, Chen R. Model interpretability for precision medicine. *J Pers Med.* 2016;6(2):17.
106. Arora S, Doshi-Velez F. A survey of methods for explaining black box models. *arXiv.* 2018.
107. Ghassemi M, Naumann T, Schulam P, Beam AL, Chen IY, Ranganath R. Challenges and opportunities in machine learning for health. *AMIA Jt Summits Transl Sci Proc.* 2020;2020:191-200.
108. Rajpurkar P, Chen E, Banerjee O, et al. AI in health care: hope and promise. *NEJM Catal.* 2022;3(1):1-13.

109. Shaikhina T, Khovanova NA. Handling limited datasets in medical AI. *Int J Med Inform.* 2017;104:62-75.
110. Johnson AEW, Pollard TJ, Shen L, *et al.* MIMIC-III critical care database. *Sci Data.* 2016;3:160035.
111. Goldstein BA, Navar AM, Carter RE. Beyond regression in cardiovascular risk prediction. *Eur Heart J.* 2017;38(23):1805-14.
112. Deo RC. Machine learning in medicine. *Circulation.* 2015;132(20):1920-30.
113. Beam AL, Manrai AK, Ghassemi M. Big data in health care. *JAMA.* 2019;322(15):1523-4.
114. Xie J, Shi F, Wu D, *et al.* Explainable AI in medical imaging. *Med Image Anal.* 2021;73:102191.
115. Holzinger A, Carrington A, Müller H. Measuring the quality of explanations. In: *Machine Learning and Knowledge Extraction.* 2020. p. 169-89.
116. Amann J, Blasimme A, Vayena E, Frey D, Madai VI. Explainability for AI in healthcare. *BMC Med Inform Decis Mak.* 2020;20:310.
117. Lauritsen SM, Kristensen M, Olsen MV, *et al.* Explainable AI model to predict acute critical illness. *J Med Internet Res.* 2020;22(11):e21704.
118. Shortreed SM, Laber EB, Lizotte DJ, Stroup TS, Pineau J. Reinforcement learning for clinical decision-making. *Med Decis Making.* 2011;31(3):397-406.
119. Gottesman O, Johansson F, Komorowski M, *et al.* Guidelines for reinforcement learning in healthcare. *Nat Med.* 2019;25(1):16-8.
120. Yu C, Liu J, Nemati S, Sun J. Reinforcement learning in healthcare: a survey. *ACM Comput Surv.* 2021;55(1):1-36.
121. Chen M, Hao Y, Cai Y, Wang Y, Sun L. Privacy-preserving machine learning for healthcare. *IEEE Internet Things J.* 2022;9(6):4444-67.
122. Rieke N, Hancox J, Li W, *et al.* The future of digital health with federated learning. *NPJ Digit Med.* 2020;3:119.
123. Yang Q, Liu Y, Chen T, Tong Y. Federated machine learning: concept and applications. *ACM Trans Intell Syst Technol.* 2019;10(2):12.

Cite this article: Jain K, Kadam D, Thakur S, Dhole P. Artificial Intelligence/Machine Learning in Pharma Analysis and Quality Control: A Real-World Upgrade. *Indian J of Pharmaceutical Education and Research.* 2026;60(2s):s375-s384.